Strategic partnerships Keystone Nano offers co-development programs alongside an internal development track, presenting a clear path for pharmaceutical and biotech partners seeking to accelerate nanotechnology-based drug delivery and specialty chemistries.

Targeted delivery stack Their NanoJackets and Nanoliposomes provide biocompatible, tunable nanoparticle platforms capable of encapsulating actives and enabling targeted delivery, which can be pitched to partners prioritizing improved tumor targeting and multi-omics therapeutic strategies.

Pain-point alignment With a focus on cancer therapeutics and difficult industrial chemistries, position Keystone Nano to collaborators facing solubility, stability, and delivery challenges that common nanotech platforms struggle to address.

Early-stage collaboration The small company size and revenue range indicate nimble, relationship-driven sales opportunities with flexibility for pilots, co-development agreements, and fast-tracked tech evaluations with academic and biotech partners.

Market readiness signals Licensing of Penn State patented NanoJackets and demonstrated liposome capabilities across melanoma, breast cancer, and leukemia suggest credible proof points to use in commercialization pitches and joint venture discussions with mid-market pharma.